A combined vaccine against hepatitis A and B in children and adolescents

Pediatric Infectious Disease Journal

Volumn 18, Issue 2, 1999, Pages 109-114

  Diaz Mitoma, Francisco ^a   Law, Barbara ^b   Parsons, James ^c  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c SmithKline Beecham Pharmaceuticals   (Canada)

Author keywords

Hepatitis A; Hepatitis B; Vaccine

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; GEOMETRY; HEADACHE; HEPATITIS A; HEPATITIS B; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SERODIAGNOSIS; VACCINATION; VOMITING;

EID: 0032996174     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199902000-00006     Document Type: Article

References (35)

1. Kane M, Alter M, Hadler S, et al. Hepatitis B infection in the United States: recent trends and future strategies for control. Am J Med 1989;87(Suppl 3A):11S-13S.
2. Koff R. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992;10 (Suppl 1):15S-17S.
3. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995;13:S47-9.
4. Pearce N. Hepatitis B virus: the importance of age at infection. NZ J Med 1988:788-9.
5. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8:S18-23.
6. O'Grady J. Management of acute and fulminant hepatitis A. Vaccine 1992;10(Suppl 1):21S-23S.
7. Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A: a review of 14 cases and literature survey. Medicine 1992;71: 14-23.
8. Nordenfelt E. Hepatitis A in Swedish travellers. Vaccine 1992;10(Suppl 1):73S-74S.
9. Hepatitis Surveillance Report No. 56. Atlanta: Centers for Disease Control and Prevention, 1996:36 pp.
10. Smith PF, Grabau JC, Werzberger A, et al. The role of young children in a community-wide outbreak of hepatitis A. Epidemiol Infect 1997;118:243-52.
11. World Health Organization. Informal consultation on quadrivalent diphtheria, tetanus, pertussis, hepatitis B vaccine. Final Report. Geneva: WHO, 4-15 May 1992:1-12.
12. André F. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990;8(Suppl): S74-8.
13. Moyes C, Milne A. Immunogenicity of a rccombinant yeastderived hepatitis B vaccine (Engerix B) in children. NZ Med J 1988;101:162-4.
14. Balcarek KB, Bagloy MR, Pass RF, Schiff ER, Krause DS. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995;171(Suppl l):S70-2.
15. Lee SD, Lo KJ, Chan CY, Yu MY, Wang YJ, Safary A. Immunogenicity of an inactivated hepatitis A vaccine in children. Gastroenterology 1993;104:1129-32.
16. Kallinowski B, Bock HL, Clemens R, Theilmann L. Immunogenicity and reactogenicity of a combined hepatitis A/B candidate vaccine: first results. Liver 1996;16:271-3.
17. Bruguera M, Bayas JM, Vilella A, et al. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults. Vaccine 1996;15:1407-11.
18. Leroux-Roels G, Moreau E, Desombre I, Safary A. Safety and immunogenicity of a combined hepatitis A and hepatitis B vaccine in young healthy adults. Scand J Gastroenterol 1996;31:1027-31.
19. Fields, BN, Knipe DM, Chanock RM, et al. Fields virology. 3rd ed. New York: Raven Press, 1996:735-82, 2703-807.
20. West DJ, Calandra GB. Vaccine induced immunologie memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996;ll:1019-25.
21. Howard PA, Haley C. Duration of immunity from hepatitis B vaccine. Drug Intell Clin Pharm 1988;22:985-7.
22. International Group. Immunization against hepatitis B. Lancet 1988;l:875-6.
23. ACIP. Recommendations for protection against viral hepatitis. MMWR 1985;34:313-35.
24. ACIP. Update on hepatitis B prevention. MMWR 1987;36: 353-67.
25. Schiff GM, Sherwood JR, Zeldis JB, Krause DS. Comparative study of the immunogenicity of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adolesc Health 1995;16:12-17.
26. Goldfarb J, Mcdendorp SV, Nagamori K, Buscarino C, Krause D. Comparison study of the immunogenicity of 5- and 10-/ig dosages of a recombinant hepatitis B vaccine in healthy children. Pediatr Infect Dis J 1996;15:768-71.
27. Hallauer J. VHPB: summary of strategies and recommendations: Viral Hepatitis Prevention Board. Vaccine 1995; 13(Suppl l):S61-3.
28. World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995;73:15-20.
29. Marwick C. 'Catch-up' hepatitis protection for adolescents. JAMA 1994;272:1730.
30. Stewart P, MacDonald N, Manion I. School-based hepatitis B immunization program: follow-up of non-participants at first school clinic. Can J Public Health 1997;88:192-6.
31. Hollinger FB. Comprehensive control (or elimination) of hepatitis B virus transmission in the United States. Gut 1996; 38(Suppl 2):S24-30.
32. Lam LP, McLaws ML. Hepatitis B vaccination coverage of Vietnamese children in south-western Sydney. Aust N Z J Public Health 1998;22:502-4.
33. McMahon B J, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J Infect Dis 1995;171: 676-9.
34. Van Damme P, Thoelen S, Gramm M, De Groote K, Safary A, Meheus A. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity and long-term antibody persistence. J Med Virol 1994;44:446-51.
35. Jilg W, Schmidt M, Dienhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet 1984;2: 458.